Concomitant background medication usage may influence the observed risk of acute pancreatitis or pancreatic cancer, either through confounding or diluting the risk attributable to GLP‐1 RAs [8, 9, 10, 11]. This evidence concerns the gene GCG and familial pancreatic carcinoma.